Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Atrial Fibrillation Treatment: Efficacy of Early vs. Delayed Catheter Ablation. A Meta-Analysis Based on Observational Studies.
Anno:
2025
Background: The optimal timing for catheter ablation (CA) in patients with atrial fibrillation (AF) remains uncertain. Objective: This study aims to evaluate whether early catheter ablation (within 1 year of diagnosis) compared to delayed catheter ablation (≥1 year) is associated with a lower rate of arrhythmia recurrence. Methods: Following…
Leggi di più
HEALTH LITERACY AND ITS IMPACT ON OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION: A PROSPECTIVE COHORT STUDY
Anno:
2025
Background: Health literacy (HL) is a risk factor for clinical outcomes in patients with cardiovascular diseases. This study explored HL levels and their impact, alongside clinical and nursing factors, on mortality, hospital readmissions, and emergency department (ED) visits in patients with atrial fibrillation. Methods: A prospective cohort study was…
Leggi di più
Atrial Cardiomiopathy is caused by bone marrow dysfunction via folate cycle disorders and dyserythropoiesis
Anno:
2025
Background: It is accepted that Atrial Fibrillation (AF) does not explain the wholeness of embolic strokes, this forcing postulation of a broader Atrial Cardiomyopathy (AC) entity. Left atrial fibrosis (Fib) is the marker of AC but its pathogenesis is not focused. Folate cycle disorders (FCD) are a dysmetabolism partly…
Leggi di più
Sodium-Glucose Cotransporter-2 Inhibitors Reduce the Risk of Atrial Fibrillation Recurrence After Catheter Ablation
Anno:
2025
Background: Recent studies have suggested a potential antiarrhythmic role for Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in patients with atrial tachyarrhythmias. However, their effects on reducing the recurrence of atrial fibrillation (AF) following catheter ablation (CA) have not been thoroughly investigated. Objective: This study aimed to determine whether SGLT2i can reduce…
Leggi di più
Impact of vein of Marshall ethanol infusion combined with anatomical lesions in patients with persistent atrial fibrillation
Anno:
2025
Background: The optimal ablation treatment for persistent atrial fibrillation (PeAF) patients is still debated. The vein of Marshall ethanol infusion (VOM-EI) seems to be a good option but more data need. Purpose: The aim of our study is to evaluate the incidence of AF recurrences in a PeAF population…
Leggi di più
DOUBLE INTERATRIAL SEPTUM: A CHALLENGING CONGENITAL ABNORMALITIES IN CLINICAL PRACTICE
Anno:
2025
Introduction Double atrial septum (DIAS) is a very rare congenital abnormality, mostly asymptomatic, in which two septa separate the atria, with a chamber between the two septa (IAC). In rare cases, it may predispose to thromboembolic events (STROKE or TIA), which can occur due to blood stasis in the…
Leggi di più
Evaluation of a 6-Lead Event Recorder (Kardia6L) for Diagnosing Arrhythmias in Patients with Paroxysmal Palpitations
Anno:
2025
Introduction: Atrial fibrillation (AF) is one of the most common arrhythmias and its diagnosis is often challenging yet crucial for therapeutic, prognostic, and quality-of-life considerations. Event recorders may offer an efficient solution for diagnosing AF or other arrhythmias in patients with paroxysmal palpitations. We tested a 6-lead event recorder (Kardia6L) for…
Leggi di più
Remote monitoring of heart failure parameters after atrial fibrillation ablation with pulsed-filed energy: an exploratory analysis
Anno:
2025
Background Catheter ablation (CA) of atrial fibrillation (AF) is recognised as an important strategy to improve systolic disfunction and to reduce mortality in selected patients with heart failure (HF). Nowadays, pulsed-field-ablation (PFA) represents a revolutionary energy source mostly used to perform fast and effective CA of AF. Remote monitoring…
Leggi di più
ANTICOAGULATION IN HYPERTROPHIC CARDIOMYOPATHY AND ATRIAL FIBRILLATION: A SINGLE-CENTRE EXPERIENCE.
Anno:
2025
Rationale and aim Based on latest European guidelines, all patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) should receive anticoagulant therapy irrespective of their thrombotic risk measured by CHA2DS2-VA score (CHA2DS2-VASc score before 2024 guidelines). The aim of our study was to assess the implementation and type of…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram